Cardiac Biomarkers Market Insights 2025-2034: Growth Forecast and Strategic Priorities

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cardiac Biomarkers Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the cardiac biomarkers market has experienced a swift expansion. The market is projected to escalate from $18.99 billion in 2024 to $21.32 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. The stronghold growth in the historic time frame can be accredited to factors such as heightened healthcare spending, FDA endorsements and regulatory support, the maturing population, awareness campaigns, highly sensitive troponin tests, and the surge in cardiovascular diseases.

Cardiac Biomarkers Market Size Forecast: What's the Projected Valuation by 2029?
It's anticipated that the cardiac biomarkers market will experience significant expansion in the coming years, forecasting to reach "$36.51 billion in 2029. This shows a compound annual growth rate (CAGR) of 14.4%. Factors such as the increasing prevalence of chronic diseases, a greater focus on early illness detection, the growth of the elderly populace, development in emerging markets, and emphasis on biomarker panels are all contributing to the projected growth within this period. During this forecast period, key trends to note include the shift towards patient-centric healthcare models, the use of AI and machine learning tools, digital health incorporation, innovative technological advancements in biomarker discovery, multi-marker panels, and the uptake of liquid biopsy in cardiovascular medicine.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

What Are the Drivers Transforming the Cardiac Biomarkers Market?
An increasing number of cardiovascular illnesses are anticipated to spur the expansion of the cardiac biomarker market. These are conditions that impact the heart and blood vessels, including coronary artery disease, heart failure, and stroke. Cardiac biomarkers, which are released into the blood when certain cardiovascular conditions such as myocardial infarction, heart failure, and arrhythmias occur, can be detected through laboratory tests and offer significant diagnostic and prognostic data. For example, data from the British Heart Foundation, a cardiovascular research charity in the UK, revealed in September 2024 that about 7.6 million individuals suffer from heart and circulatory diseases in the UK, with roughly 4 million men and 3.6 million women affected. These ailments are accountable for about 27% of all deaths in the UK, resulting in over 170,000 deaths a year or approximately 480 deaths daily, equating to one death every three minutes. Consequently, the cardiac biomarker market is growing due to the increasing prevalence of cardiovascular diseases.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

What Long-Term Trends Will Define the Future of the Cardiac Biomarkers Market?
The cardiac biomarker market is seeing an influx of innovation as a result of technological advancements, a growing trend embraced by many market players. For example, Mindray, a medical devices company based in China, introduced new high-sensitivity cardiac biomarkers, troponin I (hs-cTnI), and NT-proBNP, in October 2023. The aim is to optimize the diagnosis and management of cardiovascular diseases (CVDs). The hs-cTnI biomarker is crucial for detecting myocardial injury, offering a high detection rate and minimal inaccuracies, making it commendable for early screening and risk evaluation in conditions such as Acute Coronary Syndrome (ACS). On the other hand, NT-proBNP shines as a reliable marker for heart failure, aiding in its detection and control, showcasing exceptional accuracy and negligible disruption from common heart medications. Combined, these biomarkers can enhance clinical decision-making under pressing cardiovascular circumstances.

Which Segments in the Cardiac Biomarkers Market Offer the Most Profit Potential?
The cardiac biomarkers market covered in this report is segmented -

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications
4) By End User: Hospitals, Specialty Clinics

Subsegments:
1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels
2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels
3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels
4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels
5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels
6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

Which Firms Dominate the Cardiac Biomarkers Market by Market Share and Revenue in 2025?
Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

Which Regions Offer the Highest Growth Potential in the Cardiac Biomarkers Market?
North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.